Quick answer
What is Amylin?
Built from index records dated 2026-10-09 to 2026-10-13 Compiled by an automated pipeline, checked by The Peptide Observer editorial desk. No qualified clinical reviewer. How this site works
Amylin is a peptide, grouped on this site under Amylin and amylin receptor agonists, and the 12 research records kept here are 2 from studies in rats or mice and 10 that do not state what kind of study it is.
The literature search returned 3,167 records. This site keeps 12 of them, which is 0.38 per cent of what came back.
What it is
This site puts it in the Amylin and amylin receptor agonists group.
The endogenous ligand of the amylin receptors, which the retrieved records describe as calcitonin receptor and receptor activity-modifying protein complexes; its aggregation into islet amyloid dominates the retrieved literature.[1, 2]
Stated in the titles of the cited 1999 Molecular Pharmacology and 2011 Physiological Reviews papers.
What kind of records
The records kept here are animal and laboratory studies only.
That sentence is produced by counting, not by reading. What was counted: no interventional human trial record; 2 rodent and 0 in vitro records among 12.
What this does not settle
- What it does in a body. Counting records is not reading them, and nothing here has been read in full.
- Whether it causes harm. No adverse-effect row was taken from any source for this entry.
- How long it lasts. No pharmacokinetics source was retrieved for this entry.
- What the other 3,155 retrieved records say. They are not in this index.
The longer explanation
Where this comes from
The records cited above, in full.
- Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product. Molecular pharmacology (1999). pmid:10385705
- Islet amyloid polypeptide, islet amyloid, and diabetes mellitus. Physiological reviews (2011). pmid:21742788